Understanding the applications of apheresis in treating various diseases

The Transfusion Medicine Service in the UAB Department of Pathology performs therapeutic apheresis on patients who have an illness associated with an abnormal cellular or plasma-based blood component.
Written by: Hannah Buckelew
Media contact: Adam Pope


Stream apheresisThe Transfusion Medicine Service in the UAB Department of Pathology performs therapeutic apheresis on patients who have an illness associated with an abnormal cellular or plasma-based blood component.Apheresis, a specialized blood-filtering technique, plays a crucial role in treating a variety of diseases. To better understand the role of apheresis in transfusion medicine, Katayoun Fomani, M.D., an associate professor in the University of Alabama at Birmingham Department of Pathology and program director of the Transfusion Medicine Fellowship, explains its significance.

“The Transfusion Medicine Service in the Department of Pathology performs therapeutic apheresis on patients who have an illness associated with an abnormal cellular or plasma-based blood component,” Fomani said. “The abnormal parts of the blood are isolated and removed, then the normal components of the patient’s blood are returned to the patients. The procedures can be done as inpatient or outpatient, depending on the disease and the patient’s conditions.”

Examples of apheresis protocols include:

  • Red blood cell exchange: Removes and replaces a patient’s red blood cells
  • Hematopoietic stem cell harvest: Collects hematopoietic stem cells
  • Plasma exchange: Removes plasma and replaces it with donor plasma or albumin
  • White blood cell reduction: Reduces the number of white blood cells in a patient’s blood 
  • Platelet reduction: Reduces the number of platelets in a patient’s blood 
  • Extracorporeal photopheresis: A procedure in which blood is removed from the body and treated with ultraviolet light and drugs that become active when exposed to light. The blood is then returned to the body. It is being studied in the treatment of some blood and bone marrow diseases, transplant rejection, and graft-vs-host disease or GVHD.

“During therapeutic apheresis, the patient’s blood is passed through the apheresis machine that separates out abnormal components and returns the remaining components to the patient,” Fomani said. “The procedure can take one to six hours. In some cases, the abnormal components can be manipulated and cycled back into the patient, turning them into soldier cells to fight disease.”

Therapeutic apheresis is used in the treatment of several common conditions.

Sickle cell disease

In this genetic condition, red blood cells are shaped abnormally and cannot carry oxygen through the body effectively. If a patient develops a sickle cell crisis, their sickled red blood cells can be removed and replaced with healthy cells from a blood donor.

1208470076214574.7zCcwmHp7BIPFsU26lGD height640Katayoun Fomani, M.D.Myasthenia gravis

In this condition, an abnormal antibody in the plasma interferes with the communication between nerves and muscles. With apheresis, plasma can be separated and removed from the patient’s blood and replaced with human albumin.

Thrombotic thrombocytopenic purpura (TTP)

This rare blood disorder causes platelet clumps to form throughout the body due to a lack of a needed blood enzyme. The most effective treatment is to remove plasma, followed by replacement with normal donor plasma, which contains the needed enzyme.

Stem cell transplants

Stem cells, immature cells that develop in the bone marrow, can grow into red blood cells, white blood cells or platelets. In patients with some types of cancers of the blood, such as leukemia and lymphoma, those stem cells can be harvested from the patient by apheresis and then returned after the patient has gone through chemotherapy or other treatments.

“We want to bring further awareness to apheresis in transfusion medicine because its impact is typically behind the scenes,” Fomani said. “This therapeutic strategy is saving lives here at UAB.”